je.st
news
Tag: merck
Merck Launches New Program That Encourages Women to Rule the Real Talk and Prioritize Their Sexual Health
2015-06-11 14:00:20| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Survey Reveals Women Avoid Crucial Conversations with Partners and Health Care Providers, Including Discussions about Birth Control Options KENILWORTH, N.J.- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the results of a recent on-line survey about womens views on relationships and sex, which found that women are less assertive about initiating discussions about their sexual health than they are about other important areas of their lives. Thats why Merck is launching an educational campaign called Rule the Real Talk with Dr. Logan Levkoff, relationship and sex expert, and Dr. Language: English read more
Tags: their
real
health
program
Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints
2015-06-10 14:46:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. & SEOUL, South Korea Data Presented for the First Time at the EULAR Annual Meeting Phase 1 Data for SB2, SB4 and SB5, an Investigational Biosimilar of Humira (Adalimumab), also Presented KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced that pivotal Phase 3 clinical studies of SB4, an investigational biosimilar of Enbrel (etanercept), and SB2, an investigational biosimilar of Remicade (infliximab), met their primary endpoints, demonstrating equivalence to the originator medicine in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy. Language: English Contact: Merck Media:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orMerck Investors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879orSamsung Bioepis Media:Jamyung Cha, (82) 32-455-6137orSamsung Bioepis Investors:Sungjoon Park, (82) 32-455-6120 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: met
primary
studies
phase
No Heart Safety Issues Seen With Merck Januvia Diabetes Drug: Study
2015-06-09 17:50:34| Biotech - Topix.net
Details of a large heart safety study presented on Monday appear to give Merck and Co's diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker's biggest product. Merck in April said the study, called Tecos, of 14,724 patients with type 2 diabetes and a history of heart disease demonstrated that adding Januvia to usual care did not increase major heart problems any more than adding a placebo, removing a cloud that has been holding back sales of the medicine and the company's share price.
Tags: issues
study
heart
safety
Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies
2015-06-01 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & BERKELEY, Calif. Studies to Evaluate the Combination of Dynavaxs SD-101 with Two Immunotherapies from Mercks Pipeline, KEYTRUDA (pembrolizumab) and MK-1966 Collaboration Includes First-in-human Study for MK-1966, a New Investigational Anti-interleukin-10 (anti-IL-10) Immunomodulator from Mercks Rapidly Growing Immuno-oncology Pipeline KENILWORTH, N.J. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orMerck Investor Relations:Justin Holko, 908-740-1879orDynavax Investor/Media Relations:Michael Ostrach, 510-665-7257 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: combination
collaboration
announce
investigating
TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA (pembrolizumab)
2015-05-30 20:00:20| Merck.com - Product News
Dateline City: WALTHAM, Mass., and KENILWORTH, N.J. Clinical Trial Will Evaluate TESAROs PARP Inhibitor with Mercks Anti-PD-1 Therapy in Patients with Breast and Ovarian Cancers WALTHAM, Mass., and KENILWORTH, N.J., May 30, 2015 TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a collaboration to evaluate the combination of TESAROs niraparib plus Mercks anti-PD1 therapy, KEYTRUDA (pembrolizumab), in a Phase 1/2 clinical trial. Language: English read more
Tags: study
combination
collaborate
merck
Sites : [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] next »